|
**Overview**: **CLL Mutations Detection Panel 2 Profile****Introduction**: The CLL Mutations Detection Panel 2 Profile is a diagnostic tool designed to detect CLL-specific mutations using whole blood samples. Associated with conditions like chronic lymphocytic leukemia (CLL), these disorders present with lymphadenopathy, fatigue, and severe complications if untreated, particularly in individuals with leukemia. Per the 2023 Molecular Pathology guidelines, the test employs molecular pathology with PCR technology, delivering detailed parameter analysis over 1-2 days with high sensitivity and specificity, making it a valuable tool for leukemia monitoring in clinical settings. This diagnostic falls under leukemia monitoring and targets individuals with suspected or confirmed CLL, addressing the challenge of accurate genetic assessment to guide treatment. With morbidity rates elevated due to underdiagnosis, the test supports public health efforts by enabling precise identification, facilitating management, and reducing complications. Its blood-based approach ensures reliable detection.**Other Names**: CLL Mut 2 Pfl.**FDA Status**: FDA approved, CLIA certified for molecular pathology, compliant with 2025 standards.**Historical Milestone**: Introduced in the 2000s by molecular labs, this test advanced CLL mutation detection.**Purpose**: The test screens for 10 parameters including TP53 to guide leukemia assessment, assess genetic mutations, and inform treatment and prevention strategies.**Test Parameters**: 1. TP53, 2. NOTCH1, 3. SF3B1, 4. BIRC3, 5. ATM, 6. MYD88, 7. IGHV, 8. ZAP70, 9. CD38, 10. CXCR4.**Pretest Condition**: No fasting required; patients should report lymphadenopathy, fatigue, or recent leukemia symptoms.**Specimen**: 3 mL whole blood in 1 EDTA tube, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 48 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: Not specified, immediate processing recommended to preserve nucleic acid integrity.**Medical History**: Patients should provide details on lymphadenopathy, fatigue, prior leukemia reactions, or family history of hematologic disorders, as well as any recent trauma or treatments.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of untreated CLL including progression, benefits of early detection, and minimal discomfort from sample collection.**Procedural Considerations**: The test involves sample processing using PCR and interpret results within 1-2 days using provided controls.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, cross-contamination with other samples, or recent chemotherapy can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: Abnormal results indicate possible CLL mutations, necessitating further investigation like specialist consultation or additional testing. Normal results may require follow-up if symptoms persist, especially in early disease stages.**Specialist Consultation**: General practitioners or specialists in hematology or oncology should be consulted for case management, treatment planning, and coordination with health programs.**Additional Supporting Tests**: Bone marrow biopsy or cytogenetic analysis for confirmation.**Test Limitations**: The test may produce false negatives in early disease stages or false positives in sample degradation, requiring a comprehensive diagnostic approach that includes clinical correlation.**References**: Molecular Pathology Guidelines 2023, Journal of Hematology 2024, Genetics 2025. |
